%20(1).svg)
Live Webinar - Optimizing SDD Development: Risk-Based Strategies for Spray Dried Dispersion Process Qualification Success
Register for our latest webinar hosted by American Pharmaceutical Review! Coming up September 23rd.
Recent trends in the development of enabled drug products containing spray-dried dispersions (SDDs) demonstrate the need for early determination of process and product risk throughout the development lifecycle to reduce development time and material cost. These risks can help inform development strategies to bolster process knowledge from early clinical manufactures up through process performance qualification (PPQ), bolstering the overall time available for process optimization prior to commercialization.
This discussion will highlight the overall process qualification lifecycle for SDDs and the strategies that Seràn BioScience typically uses to support SDD intermediates throughout this process using a “Right from the Start” philosophy. These strategies are aimed at informing process decisions early in the development lifecycle while minimizing development API requirements to minimize process risk, accelerate timelines, and overall improve patient outcomes.
In this webinar you’ll learn:
· Overview of the process qualification workflow as related to spray-dried intermediates
· Understand the typical scaling parameters that define the spray drying process design space and how these variables can be informed at the small scale and translate to production scale
· Understand how to apply a risk-based framework to identify an appropriate development strategy for different drug product intermediates and other problem statements
Date: September 23, 2025
Time: 11am PT/2am ET/6pm GMT
Live Q&A following the webinar. Register your interest now!
REGISTER HERE >>>SIGN ME UP!
Tony Vickery is a Principal Engineer in the Process and Product Development group at Seràn Bioscience. He leads a team of engineers responsible for developing processes related to particle engineering and enabled drug product intermediates (i.e. spray drying, hot melt extrusion, particle size reduction, etc.). His team is also responsible for the scale-up development efforts required to take a process fit for early clinical manufacturing to the late phase clinical and commercial production scale. During his time at Seràn, Tony has been responsible for scaling various SDD intermediates to the production scale, designing and managing Seràn’s development manufacturing lab, and implementing safety and workflow procedures to improve operational functionality.
Tony has worked in the CDMO space for nine years, primarily focused on early and late phase process development related to enabled drug product intermediates, including spray-dried dispersions and inhalation products. He holds a B.S. in Bioengineering from Oregon State University.
About Serán
Serán BioScience, LLC, is a science-driven drug development partner, recognized as a world leader in drug development. Utilizing a foundation of physical and chemical science, Serán designs robust formulations and engineered solutions to some of the industry's toughest drug product problems. Our experience and background cover a wide range of pharmaceutical manufacturing concepts bringing our world-class expertise to you and your drug product. Serán’s team has decades of experience developing complex drug molecules into enabling medicines. With every addition to our team, we further our commitment to our clients’ success. From preclinical to GMP and beyond, Serán is here to support you and your drug product every step of the way.
For more information, email us at hello@seranbio.com.
Contact
Brinette Holdren
Director of Marketing
Serán BioScience, LLC
63047 Layton Ave,
Bend, OR 97701 USA
Phone: (541)-237-8501
www.seranbio.com
.svg)